142 related articles for article (PubMed ID: 8050212)
1. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients.
el-Shahawy MA; Francis R; Akmal M; Massry SG
Clin Nephrol; 1994 May; 41(5):308-13. PubMed ID: 8050212
[TBL] [Abstract][Full Text] [Related]
2. [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients].
Kinugasa E; Nabeshima K; Niikura K; Kawabe S; Akizawa T; Kitaoka T; Koshikawa S
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1109-16. PubMed ID: 2287103
[TBL] [Abstract][Full Text] [Related]
3. Improvement of bleeding time, platelet aggregation and platelet count during CAPD treatment.
Arends JP; Krediet RT; Boeschoten EW; van der Lelie J; Veenhof CH; von dem Borne AE
Proc Eur Dial Transplant Assoc; 1981; 18():280-5. PubMed ID: 7329972
[TBL] [Abstract][Full Text] [Related]
4. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
[TBL] [Abstract][Full Text] [Related]
5. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma.
Zwaginga JJ; IJsseldijk MJ; de Groot PG; Kooistra M; Vos J; van Es A; Koomans HA; Struyvenberg A; Sixma JJ
Thromb Haemost; 1991 Dec; 66(6):638-47. PubMed ID: 1665596
[TBL] [Abstract][Full Text] [Related]
6. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
[TBL] [Abstract][Full Text] [Related]
7. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
[TBL] [Abstract][Full Text] [Related]
8. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
[TBL] [Abstract][Full Text] [Related]
9. [Effect of unfractionated and low-molecular-weight heparin on platelet aggregation and in vitro bleeding time in dogs].
Nimmerfall K; Mischke R
Dtsch Tierarztl Wochenschr; 1999 Oct; 106(10):439-44. PubMed ID: 10589154
[TBL] [Abstract][Full Text] [Related]
10. [The effect of recombinant human erythropoietin on thrombocyte aggregation capacity and on the blood prostanoid level in patients with chronic kidney failure on hemodialysis].
Rud'ko IA; Pokrovskiĭ IuA; Ermolenko VM; Kubatiev AA
Ter Arkh; 1991; 63(10):128-30. PubMed ID: 1805410
[TBL] [Abstract][Full Text] [Related]
11. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients.
van Geet C; Hauglustaine D; Verresen L; Vanrusselt M; Vermylen J
Thromb Haemost; 1989 Feb; 61(1):117-21. PubMed ID: 2749585
[TBL] [Abstract][Full Text] [Related]
12. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
Hertfelder HJ; Bös M; Weber D; Winkler K; Hanfland P; Preusse CJ
Semin Thromb Hemost; 2005; 31(4):426-40. PubMed ID: 16149021
[TBL] [Abstract][Full Text] [Related]
13. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
[TBL] [Abstract][Full Text] [Related]
14. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
Roger SD; Baker LR; Raine AE
Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
[TBL] [Abstract][Full Text] [Related]
15. Enhanced platelet reactivity with erythropoietin but not following transfusion in dialysis patients.
Roger SD; Piper J; Tucker B; Raine AE; Baker LR; Kovacs IB
Nephrol Dial Transplant; 1993; 8(3):213-7. PubMed ID: 8385286
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
17. Inherited heterogenous defect in platelet aggregation selectively with ADP and epinephrine--a series of 25 cases.
Saxena R; Gupta M; Gupta S; Kannan M; Ahmed RP; Choudhry VP
Indian J Pathol Microbiol; 2005 Jul; 48(3):345-8. PubMed ID: 16761747
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
20. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
